Home » Stocks » Onconova Therapeutics

Onconova Therapeutics, Inc. (ONTX)

Stock Price: $1.14 USD 0.07 (6.54%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
Pre-market: $1.18 +0.04 (3.51%) Aug 10, 7:46 AM

Stock Price Chart

Key Info

Market Cap 198.56M
Revenue (ttm) 2.17M
Net Income (ttm) -19.00M
Shares Out 174.18M
EPS (ttm) -0.36
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $1.14
Previous Close $1.07
Change ($) 0.07
Change (%) 6.54%
Day's Open 1.03
Day's Range 1.03 - 1.15
Day's Volume 7,898,744
52-Week Range 0.10 - 2.84

More Stats

Market Cap 198.56M
Enterprise Value 167.53M
Earnings Date (est) Aug 12, 2020
Ex-Dividend Date n/a
Shares Outstanding 174.18M
Float 166.98M
EPS (basic) -0.24
EPS (diluted) -0.36
FCF / Share -0.13
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 8.56M
Short Ratio 1.20
Short % of Float 4.55%
Beta 2.61
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 91.63
PB Ratio 8.69
Revenue 2.17M
Operating Income -19.58M
Net Income -19.00M
Free Cash Flow -20.75M
Net Cash 31.04M
Net Cash / Share 0.18
Gross Margin 100.74%
Operating Margin -903.74%
Profit Margin -876.60%
FCF Margin -957.45%
ROA -56.38%
ROE -191.75%
ROIC 289.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$2.08*
(82.46% upside)
Low
1.30
Current: $1.14
High
3.00
Target: 2.08
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014201320122011
Revenue2.181.230.795.5511.460.804.7546.191.49
Revenue Growth77.77%56.04%-85.81%-51.59%1332%-83.17%-89.71%3006.25%-
Gross Profit2.181.230.795.5511.460.804.7546.191.49
Operating Income-21.70-23.28-25.74-23.70-23.97-63.74-62.22-22.28-27.57
Net Income-21.50-20.57-24.09-19.67-23.98-63.68-62.54-29.91-26.29
Shares Outstanding14.384.120.600.300.150.140.070.010.01
Earnings Per Share-1.49-4.99-40.15-66.60-158.09-440.98-917.95-2,302.39-2,126.89
Operating Cash Flow-20.83-22.70-23.82-15.81-31.24-57.65-61.381.63-14.17
Capital Expenditures-0.06-----0.23-0.61-0.28-0.26
Free Cash Flow-20.89-22.70-23.82-15.81-31.24-57.88-61.991.35-14.43
Cash & Equivalents22.7316.974.0221.4519.8543.7110081.652.84
Total Debt--------0.62
Net Cash / Debt22.7316.974.0221.4519.8543.7110081.652.22
Assets23.6717.924.9823.2323.4547.3410583.854.46
Liabilities12.1012.5415.8418.1112.6123.7224.2540.8422.88
Book Value11.575.39-11.694.3010.0122.7580.41-158-138
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Onconova Therapeutics, Inc.
Country United States
Employees 17
CEO Steven M. Fruchtman

Stock Information

Ticker Symbol ONTX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ONTX
IPO Date July 25, 2013

Description

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule product candidates to treat cancer. Its product candidates include Rigosertib IV, which is in Phase III clinical trial for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trial for patients with higher-risk MDS; and Rigosertib oral, which is in Phase II clinical trial for patients with lower risk MDS. The company also develops Briciclib, which is in Phase I multi-site dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes. The company has a license agreement with SymBio Pharmaceuticals Limited; a license, development, and commercialization agreement with Pint International SA; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of ON 123300 in Greater China. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.